{"id":7469,"date":"2018-12-03T20:00:00","date_gmt":"2018-12-04T04:00:00","guid":{"rendered":"https:\/\/sfj-pharma.com\/?p=7469"},"modified":"2021-05-13T13:48:46","modified_gmt":"2021-05-13T21:48:46","slug":"momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira","status":"publish","type":"post","link":"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/","title":{"rendered":"Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA\u00ae"},"content":{"rendered":"\r\n<p>CAMBRIDGE, Mass.,\u00a0Dec. 03, 2018\u00a0(GLOBE NEWSWIRE) &#8212;\u00a0Momenta Pharmaceuticals,\u00a0Inc.\u00a0(Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced a revised regulatory strategy in\u00a0the United States\u00a0for M923, Momenta\u2019s proposed biosimilar to HUMIRA. Momenta had previously guided that it planned to file a Biologics License Application (BLA) to the\u00a0U.S. Food and Drug Administration\u00a0(FDA) in the fourth quarter of this year.<\/p>\r\n\r\n\r\n\r\n<p>&nbsp;<\/p>\r\n\r\n\r\n\r\n<p>With the recent\u00a0Abbvie\u00a0agreement, Momenta will be able to commercialize M923 in\u00a0the United States, pending regulatory approval, as early as\u00a0November 20, 2023. Momenta has decided to delay the filing of the BLA, which may reduce program costs in 2019 without delaying potential US market entry for M923.<\/p>\r\n\r\n\r\n\r\n<p>&nbsp;<\/p>\r\n\r\n\r\n\r\n<p>\u201cThe clarity on the US entry date provided by our settlement with\u00a0Abbvie\u00a0allows us to better align our regulatory and manufacturing strategies and enables us to defer expenses without impact to our launch timing,\u201d said\u00a0Craig Wheeler, President and Chief Executive Officer of Momenta.<\/p>\r\n\r\n\r\n\r\n<p>&nbsp;<\/p>\r\n\r\n\r\n\r\n<p><strong>About Momenta<\/strong><br \/>Momenta\u00a0is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases. Momenta\u2019s lead product candidate, M281, is a potentially best-in-class anti-FcRn antibody; M254, is a hyper-sialylated human immunoglobulin (hsIgG) designed as a high potency alternative to intravenous immunoglobulin (IVIg); and M230 (CSL730), is a potential first-in-class novel recombinant Fc multimer being developed in collaboration with CSL. Momenta also has a focused pipeline of two biosimilar candidates: M923, Momenta\u2019s wholly-owned proposed biosimilar to HUMIRA<sup>\u00ae\u00a0<\/sup>, and M710, a proposed biosimilar to EYLEA<sup>\u00ae<\/sup>\u00a0being developed in collaboration with Mylan. Momenta\u2019s two\u00a0FDA-approved complex generic products, enoxaparin sodium injection and Glatopa<sup>\u00ae<\/sup>\u00a0(glatiramer acetate injection), are marketed by its collaboration partner,\u00a0Sandoz.<\/p>\r\n\r\n\r\n\r\n<p>&nbsp;<\/p>\r\n\r\n\r\n\r\n<p>To learn more about Momenta, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DYwzLpO6eiPueKVQdUJTA_DJ-L6wn5zXM00panXcQLLkjTUseoWiXfUBFDng2_BrYmqq1PGdee4ydxqKTrHZ00GiGPVk2w6kzJOSg4OAHWM=\">www.momentapharma.com<\/a>, which does not form a part of this press release.<\/p>\r\n\r\n\r\n\r\n<p>Momenta\u2019s logo, trademarks, and service marks are the property of\u00a0Momenta Pharmaceuticals, Inc.\u00a0All other trade names, trademarks, or service marks are property of their respective owners.<\/p>\r\n\r\n\r\n\r\n<p>&nbsp;<\/p>\r\n\r\n\r\n\r\n<p><strong>Forward-Looking Statements\u00a0<\/strong><br \/>Statements in this press release regarding management&#8217;s future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about the timing of regulatory filings, the development and commercialization plans, including target launch dates, program costs for, and the potential of, M923. Forward-looking statements may be identified by words such as &#8220;believe,&#8221; &#8220;continue,&#8221; \u201cplan to\u201d, &#8220;potential,&#8221; &#8220;will,&#8221; and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, including the risk that the program costs savings will not be achieved, that the marketing approval process is expensive, time-consuming and uncertain and may prevent the Company from obtaining approvals for the commercialization of M923; and those referred to under the section &#8220;Risk Factors&#8221; in the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended\u00a0September 30, 2018\u00a0filed with the\u00a0Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the\u00a0Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company&#8217;s actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass.,\u00a0Dec. 03, 2018\u00a0(GLOBE NEWSWIRE) &#8212;\u00a0Momenta Pharmaceuticals,\u00a0Inc.\u00a0(Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced a revised regulatory strategy in\u00a0the United States\u00a0for M923, Momenta\u2019s proposed biosimilar to HUMIRA. Momenta had&#8230;<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[103],"tags":[],"class_list":["post-7469","post","type-post","status-publish","format-standard","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA\u00ae - SFJ Pharmaceuticals<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA\u00ae - SFJ Pharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.,\u00a0Dec. 03, 2018\u00a0(GLOBE NEWSWIRE) &#8212;\u00a0Momenta Pharmaceuticals,\u00a0Inc.\u00a0(Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced a revised regulatory strategy in\u00a0the United States\u00a0for M923, Momenta\u2019s proposed biosimilar to HUMIRA. Momenta had...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/\" \/>\n<meta property=\"og:site_name\" content=\"SFJ Pharmaceuticals\" \/>\n<meta property=\"article:published_time\" content=\"2018-12-04T04:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-05-13T21:48:46+00:00\" \/>\n<meta name=\"author\" content=\"Lily Xu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lily Xu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/\"},\"author\":{\"name\":\"Lily Xu\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/770e5cbce35f5f0f90d2218806ceba11\"},\"headline\":\"Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA\u00ae\",\"datePublished\":\"2018-12-04T04:00:00+00:00\",\"dateModified\":\"2021-05-13T21:48:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/\"},\"wordCount\":630,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/#organization\"},\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/\",\"url\":\"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/\",\"name\":\"Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA\u00ae - SFJ Pharmaceuticals\",\"isPartOf\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/#website\"},\"datePublished\":\"2018-12-04T04:00:00+00:00\",\"dateModified\":\"2021-05-13T21:48:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.sfj-pharma.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#website\",\"url\":\"https:\/\/www.sfj-pharma.com\/\",\"name\":\"SFJ Pharmaceuticals\",\"description\":\"Resources for Accelerated Clinical Development\",\"publisher\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.sfj-pharma.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#organization\",\"name\":\"SFJ Pharmaceuticals\",\"url\":\"https:\/\/www.sfj-pharma.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/secureservercdn.net\/198.71.233.213\/c59.835.myftpupload.com\/wp-content\/uploads\/2020\/12\/SFJ-Logo-Final-RGB.png?time=1666279552\",\"contentUrl\":\"https:\/\/secureservercdn.net\/198.71.233.213\/c59.835.myftpupload.com\/wp-content\/uploads\/2020\/12\/SFJ-Logo-Final-RGB.png?time=1666279552\",\"width\":750,\"height\":205,\"caption\":\"SFJ Pharmaceuticals\"},\"image\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/770e5cbce35f5f0f90d2218806ceba11\",\"name\":\"Lily Xu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2b733936c0f668be1f942765f61e3056?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2b733936c0f668be1f942765f61e3056?s=96&d=mm&r=g\",\"caption\":\"Lily Xu\"},\"url\":\"https:\/\/www.sfj-pharma.com\/author\/lily\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA\u00ae - SFJ Pharmaceuticals","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/","og_locale":"en_US","og_type":"article","og_title":"Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA\u00ae - SFJ Pharmaceuticals","og_description":"CAMBRIDGE, Mass.,\u00a0Dec. 03, 2018\u00a0(GLOBE NEWSWIRE) &#8212;\u00a0Momenta Pharmaceuticals,\u00a0Inc.\u00a0(Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced a revised regulatory strategy in\u00a0the United States\u00a0for M923, Momenta\u2019s proposed biosimilar to HUMIRA. Momenta had...","og_url":"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/","og_site_name":"SFJ Pharmaceuticals","article_published_time":"2018-12-04T04:00:00+00:00","article_modified_time":"2021-05-13T21:48:46+00:00","author":"Lily Xu","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Lily Xu","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/#article","isPartOf":{"@id":"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/"},"author":{"name":"Lily Xu","@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/770e5cbce35f5f0f90d2218806ceba11"},"headline":"Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA\u00ae","datePublished":"2018-12-04T04:00:00+00:00","dateModified":"2021-05-13T21:48:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/"},"wordCount":630,"commentCount":0,"publisher":{"@id":"https:\/\/www.sfj-pharma.com\/#organization"},"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/","url":"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/","name":"Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA\u00ae - SFJ Pharmaceuticals","isPartOf":{"@id":"https:\/\/www.sfj-pharma.com\/#website"},"datePublished":"2018-12-04T04:00:00+00:00","dateModified":"2021-05-13T21:48:46+00:00","breadcrumb":{"@id":"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.sfj-pharma.com\/momenta-pharmaceuticals-provides-update-on-us-regulatory-strategy-for-m923-proposed-biosimilar-to-humira\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sfj-pharma.com\/"},{"@type":"ListItem","position":2,"name":"Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/www.sfj-pharma.com\/#website","url":"https:\/\/www.sfj-pharma.com\/","name":"SFJ Pharmaceuticals","description":"Resources for Accelerated Clinical Development","publisher":{"@id":"https:\/\/www.sfj-pharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sfj-pharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.sfj-pharma.com\/#organization","name":"SFJ Pharmaceuticals","url":"https:\/\/www.sfj-pharma.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/logo\/image\/","url":"https:\/\/secureservercdn.net\/198.71.233.213\/c59.835.myftpupload.com\/wp-content\/uploads\/2020\/12\/SFJ-Logo-Final-RGB.png?time=1666279552","contentUrl":"https:\/\/secureservercdn.net\/198.71.233.213\/c59.835.myftpupload.com\/wp-content\/uploads\/2020\/12\/SFJ-Logo-Final-RGB.png?time=1666279552","width":750,"height":205,"caption":"SFJ Pharmaceuticals"},"image":{"@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/770e5cbce35f5f0f90d2218806ceba11","name":"Lily Xu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2b733936c0f668be1f942765f61e3056?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2b733936c0f668be1f942765f61e3056?s=96&d=mm&r=g","caption":"Lily Xu"},"url":"https:\/\/www.sfj-pharma.com\/author\/lily\/"}]}},"rttpg_featured_image_url":null,"rttpg_author":{"display_name":"Lily Xu","author_link":"https:\/\/www.sfj-pharma.com\/author\/lily\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.sfj-pharma.com\/category\/news\/\" rel=\"category tag\">News<\/a>","rttpg_excerpt":"CAMBRIDGE, Mass.,\u00a0Dec. 03, 2018\u00a0(GLOBE NEWSWIRE) &#8212;\u00a0Momenta Pharmaceuticals,\u00a0Inc.\u00a0(Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced a revised regulatory strategy in\u00a0the United States\u00a0for M923, Momenta\u2019s proposed biosimilar to HUMIRA. Momenta had...","_links":{"self":[{"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/posts\/7469","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/comments?post=7469"}],"version-history":[{"count":2,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/posts\/7469\/revisions"}],"predecessor-version":[{"id":8419,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/posts\/7469\/revisions\/8419"}],"wp:attachment":[{"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/media?parent=7469"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/categories?post=7469"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/tags?post=7469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}